ZURICH, Nov 17 (Reuters) - The Swiss blue-chip SMI was seen opening flat at 9,149 points on Friday, according to premarket indications by bank Julius Baer.
The following are some of the main factors expected to affect Swiss stocks:
The U.S. Food and Drug Administration on Thursday approved Roche’s Hemlibra, a new medicine for haemophilia A that the Swiss drugmaker is counting on to help to offset eroding sales of older medicines going off patent.
Roche also said it agreed to acquire Viewics, Inc. for data-driven lab business analytics.
For more, click on
* Schaffner said it expects net profit in a range of 7-9 million Swiss francs for 2016/17.
* Dufry said it has successfully refinanced its main bank credit facilities of 3.4 billion Swiss francs. The agreement extends the maturity to 2022 and the new financing structure will generate combined yearly interest savings of around 50 million francs, the company said.
* Aevis Victoria said total revenues at Sept. 30, 2017 increased by 15.4 percent to 487 million Swiss francs.
* Schweiter Technologies’s 3A Technology & Management AG has signed an agreement with Halter AG to sell its investment property in Neuhausen. The transaction will generate a book gain in the single-digit Swiss franc millions for Schweiter, the company said.
* New Value posted a first-half loss of 1.02 million francs.
* St Galler Kantonalbank said it successfully placed double tranche additional bonds.
Recent moves by the U.S. Federal Reserve to tighten its monetary policy is helping the Swiss National Bank in its campaign against the “highly valued” Swiss franc, SNB Governor Andrea Maechler said on Thursday.
Reporting by Zurich newsroom